STUDresearch · Peptide
Bronchogen
Also known as
AEDL · Ala-Glu-Asp-Leu · H-Ala-Glu-Asp-Leu-OH / H-AEDL-OH · ADEL / Ala-Asp-Glu-Leu (letter-order in some peer-reviewed titles) · peptide AEDL · respiratory bioregulator · bronchial bioregulator · lung bioregulator (Khavinson tetrapeptide) · Khavinson bronchial tetrapeptide · Bronchogen (Cytomax / cytogen capsule discussions) · bronchial mucosa tetrapeptide
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Injection / oral
Longevity & bioregulators
Whole-body — people treat this as circulating, not a local pin.
What people say
Bronchogen is the AEDL tetrapeptide discussed as a lung or bronchial bioregulator. The accessible formal evidence checked here is a rat injury-model paper, not human efficacy or pharmacokinetics.
Doses people talk about
Injection amounts and oral product schedules are separate lanes and cannot be treated as bioavailability-matched.
How it may feel
Early reports are too thin for a typical feel pattern. One account was inconclusive after a week; another tracked lung-function numbers across two injection phases but had peptide co-use and sparse measurements.
One reported first phase500 mcg SC once daily for 40 days
Evening use in one unverified self-log; the label describes chronology, not a starting recommendation.
Same report's later phase1,000 mcg SC, 6 days on / 1 day off for 7 weeks
The same author described this after a break; it is not a validated higher tier.
Broader short-course chart band~0.5–2 mg/day for ~10–20 days
Research-chemical SC/IM discussion; longer influencer schedules and oral capsule products are separate contexts.
Oral capsule product charts1–2 capsules once or twice daily with food for 20–30 days
Capsule strength is product-dependent and is not equivalent to lyophilized-vial AEDL math.
Higher oral copy~10–20 mg/day for 10–30 days
Minority secondary product-page band; not the same lane as 500–1,000 mcg injection reports.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Early accountStill inconclusive after about 1 week
- Other trackingBreathing measurements over a course; no consistent immediate felt window
Cycles people discuss
The notes contain short 10–20-day courses and longer 20–40-day or 6-on/1-off schedules. These are separate community/product patterns, not a validated human cycle.
Timing
Evening or empty-stomach injection routines and once-daily morning routines both appear in community charts. One self-log used evening SC administration; oral capsule charts instead pair use with food. No controlled timing comparison establishes a preferred routine.
Stacks
Chonluten is the most common co-mention, and BPC-157/TB-500 appeared in the most detailed self-log. Stacking prevents clean attribution.
Watch for
Human safety gap: No solid Western clinical safety tables, large RCTs, or systematic adverse-event registry for synthetic AEDL/Bronchogen.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
The checked evidence does not establish a human Bronchogen half-life.
The rat NO2 injury paper reports bronchoalveolar and tissue endpoints, not a plasma clearance estimate; community daily-course schedules do not supply PK.
Absence from these checked sources is bounded evidence, not proof that no unpublished or inaccessible PK work exists.
- Anti-inflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology (opens in a new tab)PubMed abstract: 60-day intermittent NO2 rat model; bronchoalveolar inflammatory markers, secretory IgA, surfactant protein B and bronchial epithelium endpoints.Rat injury model; abstract does not provide a human route, plasma half-life, felt duration or human safety/efficacy outcome.
Felt duration people report
The inspected community reports do not establish an acute felt duration or typical onset.
One report remained inconclusive after about a week. Another described no sleep or site-reaction signal and tracked peak flow/FEV1 over two phases, but had co-use and sparse measurements.
Very small sample, unverified products, changing health conditions, BPC-157/TB-500 co-use and self-measured lung function.
- Bronchogen for lungs (opens in a new tab)Creativetaught original post at about one week of 500 mcg daily and same-author follow-up about a year later describing the original problem as rib-related and benefit as hard to isolate.Single unverified product report, changing interpretation of the underlying problem and acknowledged concurrent interventions.
- My Bronchogen results (opens in a new tab)OwnTension6771 post: 500 mcg SC evenings for 40 days, later 1,000 mcg on a 6-on/1-off schedule for seven weeks; visible PEF/FEV1, tolerability and co-use discussion.Self-described amateur n=1, unverified product, BPC-157/TB-500 co-use, illness/instrument limits and sparse measurements; author conclusions exceed the design.
What people say
- Breathing comfort (community): Sparse multi-week logs of easier breathing / less chest tightness; almost always described as subtle if present, and heavily confounded by season, meds, cessation, and stacks. forum
- Chronic airway talk: Often paired with chronic bronchitis, smoker’s-lung, pollution, or “dirty air city” narratives; single-agent attribution is weak. forum
- Post-infection / post-COVID: Occasional “tissue support” or residual-breathlessness add-on during recovery windows — not an antiviral and not a post-COVID standard of care. anecdote
- Asthma adjunct lore: Secondary blogs list asthma alongside COPD/bronchitis as use cases; community still treats it as non-rescue adjunct at best — controllers and rescue stay primary. anecdote
- What users do not reliably report: Acute rescue of wheeze like a SABA/SAMA; large public spirometry (FEV1/FVC/PEF) gains; CT/fibrosis reversal; same-day “opened lungs.” forum
- Stack halo: Inside Bronchogen+Chonluten or multi-Khavinson kits, single-agent credit is especially weak — sequential courses sometimes discussed for cleaner n=1 tracking. forum
- Rat NO₂ COPD model (~1 mo after injury induction): Reduced remodeling hallmarks — goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration, emphysematous change; restoration of ciliated epithelium discussed (PMID 26468022, Kuzubova et al. 2015). animal
- Inflammation (same model family): Lower neutrophilic inflammation in BALF; cytokine shifts including TNF-α / IL-8 themes; macrophage composition moves toward a less neutrophil-dominant picture (companion work including PMID 30199201 lineage). animal
- Local immunity markers: Enhanced secretory IgA (sIgA) framed as barrier/mucosal immunity recovery in treated animals’ BALF. animal
- Surfactant talk: Surfactant protein B increases reported in related obstructive-lung peptide work (e.g. PMID 30199201 lineage); some vendor pages also name SP-A/SP-D — SP-B is the better-cited animal marker. animal
- Epithelium differentiation (cells): Markers such as Nkx2.1, SCGB1A1, SCGB3A2, FoxA1, FoxA2, and mucin-related genes (MUC4, MUC5AC) discussed as modulated in bronchial-cell systems. lab
- Proliferation / stress proteins: Ki67, Mcl-1, p53, CD79, NOS-3 expression themes appear in Khavinson-group writeups of bronchial cultures. lab
- Epigenetic / methylation (cells): Age- and tissue-specific DNA-methylation pattern effects on lung-associated gene promoters discussed (e.g. Ashapkin et al. lineage, PMID 25761685 class) — cell-culture observation, not a human onset curve. lab
- Histone / chromatin talk: Interaction with core histones (H1, H2B, H3, H4) and endonuclease activity modulation appear in short-peptide systematic reviews — class mechanism, not a human PD package. lab
- DNA story: AEDL/ADEL–DNA interaction; melting temperature raised ~3.1°C in microcalorimetry — marketing’s favorite hard number (PMID 21240358). lab
- Fibrosis interest (sparse): Secondary summaries mention bleomycin-type pulmonary-fibrosis or fibrotic-gene (e.g. collagen / TGF-β pathway) modulation in lab models — thinner evidence than the NO₂ COPD histology papers; treat as exploratory. animal
- Geroprotection narrative: “Preserved lung parameters in aging models” and differentiation-factor rescue in old cultures drive longevity-stack interest — still single-lab / developer-heavy literature. animal
- Progenitor / repair framing: Developer and review writeups discuss engagement of club (Clara) cells, basal cells, and type II alveolar progenitors as a structural-repair story — mechanism hypothesis, not human regeneration proof. animal
- Hoxa3 / aging cultures: Hoxa3 induction (~1.4–1.7× vs control in some culture summaries) more pronounced in aged bronchial cultures — geroprotective framing; CXCL12 often described as not moved — selective, not global “stem-cell activator.” lab
Doses people talk about
- Two culture bands (know which log you are reading): (A) Research-chem short courses ~0.5–2 mg/day × ~10–20 days SC/IM; (B) Influencer “beginner/advanced” charts at 500–1,000 mcg/day for ~40 days or multi-week 6-on/1-off — plus separate oral capsule mg schedules that are not vial-math equivalent. forum
- One reported injection phase: A self-log describes 500 mcg (0.5 mg) SC in the evening for 40 consecutive days. This is a single unverified account, not an opening-dose recommendation. forumanecdote
- Same author’s later phase: After a break, the same self-log describes 1,000 mcg (1 mg) SC on a 6-days-on/1-day-off schedule for seven weeks. It is not a validated “advanced” tier. forumanecdote
- Wider research-chem band: ~0.5–2 mg per day SC (or IM in some charts) across a short course is the range most often summarized from vendor/community sources. forum
- Higher chart outliers: Some protocol pages list ~2 mg/day as “advanced research” with matching insulin-syringe unit math; a few secondary pages drift as high as ~5 mg/day research talk — treat upper outliers as unvetted, not consensus. forum
- Pen talk: Vendor/pen discussions sometimes quote ~2 mg per dose / ~20 units, ~10 doses per pen (~10-day pen life at that setting) — product-specific concentration and unit marking, not universal. forum
- Course length (injectable short convention): Daily for ~10–20 days is the dominant research-chem “bioregulator course” pattern inherited from Russian extract-course culture. forum
- Longer injectable runs: ~20–40 consecutive days (some blogs fix on ~40 days at 500 mcg); 6-on/1-off multi-week variants at ~1 mg; rare multi-month continuous daily use is less common than cyclic courses. forum
- Oral research-vial-adjacent talk: Some tables list oral ~1–2 mg/day with low bioavailability assumed vs SC — still community math, not published human PK proof. forum
- Oral capsule / cytogen-style products: Blog language often “1–2 capsules once or twice daily with food for 20–30 days,” then multi-month break — mg-per-capsule is product-label dependent and ≠ lyophilized vial AEDL math. forum
- High oral mg claims (product-page band): A minority of secondary sites quote ~10–20 mg/day oral for 10–30 days (chronic bronchitis/COPD narrative pages) or ~10–15 mg/day for 2–4 weeks — treat as product-form or unvetted copy, not as the same protocol as 500 mcg SC vials. forum
- Vial sizes seen: 10 mg and 20 mg lyophilized research vials are common SKUs; 20 mg is the most-quoted community math anchor. forum
- Vial coverage math: At 0.5 mg/day, a 20 mg vial ≈ 40 days; at 1 mg/day ≈ 20 days; at 2 mg/day ≈ 10 days — course length and dose must match before ordering “one vial” assumptions. forum
- IM vs SC: SC dominates research-lyophilized discussion; IM appears as carry-over from older injectable tissue-extract practice — no head-to-head human bioavailability data for synthetic AEDL. forum
- AM vs PM fight: Evening / empty-stomach blogs are common in influencer protocols; other vendor charts default AM once daily for short courses — no chronotherapy trial. forum
- Uncertainty drivers: Gray-market purity, AEDL vs ADEL labeling, extract-vs-synthetic confusion, oral-mg vs injectable-mcg unit mixing, and mg-vs-mcg spreadsheet errors all weaken dose comparisons. forum
- Preclinical lab dose context (not human conversion): Vendor/research tables sometimes cite cell culture ~10–100 nM; in-vivo rodent respiratory-aging models ~1–10 µg/kg; airway-inflammation paradigms ~5–20 µg/kg; combined multi-peptide regimens ~1–10 µg/kg each (e.g. Bronchogen + Chonluten) — species/route/study-specific, not a human mcg calculator. animal
- Framing: Discussed research / vendor / blog ranges only — not advice, not prescriptions, not validated human dose-finding. Synthetic Bronchogen has no widely accepted Western clinical titration study. forum
How it may feel
- Days 1–3: No reliable early-effect data; mechanism is not acute bronchodilation — same-day “lung feel” is anecdote; injection-site awareness more common than breathing change. forum
- Early community reports: One user at 500 mcg daily called the first week inconclusive and later said the issue appeared rib-related; a separate single-user injection log reported no sleep disruption or site irritation, but included BPC-157/TB-500 and sparse lung-function measurements. forumanecdote
- Days 4–10: Active window in short 10–20 day community models; still mostly subtle or null. forum
- Weeks 1–2: Early “easier breathing” claims inconsistent; usually treated as too early for hard conclusions. forum
- Weeks 2–4 / end of short course: Common checkpoint — subtle comfort shift, less irritation/mucus narrative, or “nothing”; this window also loosely mirrors the animal course length used in rat COPD papers (extrapolation, not human proof). forum
- ~40 days (blog longer runs): Some influencer protocols treat ~40 consecutive days at 500 mcg as a full “cellular reset” length; public objective lung metrics remain rare. forum
- ~1 month (animal anchor): COPD-model treatment windows often ~1 month after NO₂ induction; communities sometimes mirror that as a research cycle length rather than 10–20 day micro-courses. animal
- Week 1 (mechanism expectation): Animal histology and inflammatory endpoints were measured after ~month-scale courses, not day-scale; epigenetic/gene-expression framing does not predict week-1 drama. animal
Cycles people discuss
- Course style: Finite short courses far more common than lifelong daily use — classic Khavinson bioregulator calendar. forum
- Typical short course (research-chem): ~10–20 consecutive days once daily injectable. forum
- Extended courses: ~20–40 days continuous (including the ~40-day 500 mcg “reset” blog model), or ~6-on/1-off multi-week variants (~7 weeks at 1 mg in advanced charts). forum
- Oral product courses: ~20–30 days of capsules common in Cytogen-style writeups; some secondary pages use 10–30 day ranges at higher mg. forum
- Breaks: Often ~4–6 months off before a planned re-run after oral courses; injectable calendars similarly use multi-month pauses; some catalogs imply ~2–3 courses/year. forum
- Seasonal / exposure re-runs: Spring–fall, pre-winter, heavy pollution seasons, wildfire-smoke periods, or post-illness restarts appear in logs. forum
- Repeat cadence: Rest, then re-run when seasonal complaints return — not a fixed trial arm; “maintenance forever” is uncommon vs high-volume peptides. forum
- Long-term continuous use: Sparse vs BPC-157, Epitalon, or GLP-1s; multi-year safety database essentially absent for synthetic AEDL. forum
- Medical caution: Don’t delay workup for infection, asthma exacerbation, progressive dyspnea, hemoptysis, hypoxia, or cardiac mimics while “waiting for a course to finish.” forum
- Animal course length vs community: Rat NO₂ models often ran ~1 month of peptide after injury induction — longer than many 10–20 day forum micro-courses; communities sometimes lengthen courses to mirror that, without human titration support. animal
Timing
- No measured clearance clock: AEDL is a four-amino-acid peptide, but size alone does not establish its human half-life. Daily course schedules in the notes are community/product customs, not evidence of depot or clearance kinetics. forum
- Epigenetic / gene-expression lore: Marketing claims “effects persist after levels fall” via chromatin/gene programs; not proven as a human PK/PD model for AEDL. forum
- Injection timing debates: Evening / empty-stomach blogs vs consistent AM once daily — no head-to-head human data. forum
- Oral vs inject: Multi-day oral capsule courses and mcg–mg injectable schedules are not interchangeable evidence streams or bioavailability-matched. forum
- Feel pattern: Gradual tissue-support narrative, not an acute on/off inhaler feel; absence of early “hit” is expected, not proof of failed product. anecdote
- Monitoring talk: Community advice sometimes includes home peak-flow / spirometer tracking across a course because subjective breath is noisy — still n=1, not a trial endpoint. forum
- PK gap: No widely cited human ADME, bioavailability, or half-life package for synthetic Bronchogen. trial
- Tissue vs blood: Circulating peptide levels (unmeasured publicly) ≠ multi-week animal histology timelines or post-course “bioregulation” lore. animal
More on what it is
- Why people search it: Chronic cough, post-viral breath, smoker/pollution exposure, COPD-model lore denser than most other Khavinson lung names, organ-bioregulator stacks, and “structural lung + mucosal” dual courses with Chonluten. forum
- Extract vs synthetic: Human-facing bioregulator product history sometimes traces to bronchial/lung tissue extracts (Cytomax-class complexes); research-chem Bronchogen is the synthetic tetrapeptide — do not treat extract claims as validated for the lyophilized vial. forum
- vs Chonluten (one line): Community lore often frames Bronchogen as “structure / epithelium / surfactant / rebuild” and Chonluten as “mucosal immunity / inflammation calm” — complementary marketing, not a trial-proven division of labor. forum
- Not this: Not a rescue inhaler, steroid substitute, antibiotic/antiviral, mucolytic, oxygen replacement, or proven COPD/asthma disease-modifying drug. forum
- What it is: Synthetic tetrapeptide most often written Ala-Glu-Asp-Leu (AEDL); Khavinson-class bronchial/lung bioregulator (~446.45 Da, formula commonly listed C₁₈H₃₀N₄O₉). trial
- Sequence caveat: Some peer-reviewed titles list Ala-Asp-Glu-Leu (ADEL) — e.g. DNA-thermostability papers — while vendors and chem sheets usually sell “AEDL / Bronchogen”; letter-order mixups are a real identity risk when matching COA to literature. trial
- Tissue target: Bronchial epithelium, alveolar pneumocytes, and pulmonary parenchyma in developer framing; often co-searched with Chonluten (different sequence — EDG tripeptide, not AEDL). forum
- Mechanism (simplified): Short-peptide DNA/chromatin interaction and tissue gene-expression talk (Nkx2.1, SCGB family, FoxA, mucins, Hoxa3, etc.) — not β-agonist, anticholinergic, or inhaled-steroid receptor pharmacology. lab
- DNA stabilizer hook: Microcalorimetry work reported ~+3.1°C DNA melting temperature (calf thymus / mouse liver DNA) — used heavily in marketing as “DNA stabilizer” (PMID 21240358). lab
- Binding detail (in vitro): Major-groove / guanine-N7 style interaction without gross helix distortion; CTG-motif and methylation-pattern selectivity hypothesized in related short-peptide papers. lab
- Evidence posture: Rat obstructive-lung (NO₂) models and bronchial-cell work denser than for Chonluten; still no large Western human RCTs or ClinicalTrials.gov dose standard for the synthetic peptide. animal
- Origin framing: Modeled on short sequences from bronchial mucosa research (murine/Eastern European bioregulator program under Vladimir Khavinson’s line), not a large endogenous hormone or recombinant growth factor. trial
Stacks
- Chonluten (most common co-mention): “Lung duo” — Bronchogen framed as structural/epithelial/surfactant rebuild, Chonluten as mucosal/immune calm (EDG tripeptide). Same short course in parallel, or sequential courses for cleaner n=1 tracking. No validated fixed ratio; vendors often sell both 10–20 mg vials separately. forum
- Chonluten stack ratios: Community does not standardize a blend formula; common pattern is each peptide at its own full course dose (e.g. both in the 0.5–2 mg/day research-chem band, or each at own oral capsule schedule) rather than a published 1:1 mg kit. Preclinical multi-peptide tables sometimes list ~1–10 µg/kg each — not a human stack recipe. forum
- Khavinson multi-organ panels: With Epitalon, Cortagen, Vesugen, Vilon, Cartalax, Pinealon, Livagen, Ovagen in multi-organ “course” kits / calendar weeks — confounds single-agent credit. forum
- Repair crossover: Occasional BPC-157, TB-500 (or TB-4), or KPV “body + lungs / inflammation” stacks — heavily confounded; stack tables sometimes put Bronchogen ~10 mg/week evening next to BPC ~250 mcg/day and TB-500 ~2 mg/week as table shorthand only. forum
- Epitalon longevity pair: Sequential or overlapping bioregulator courses in longevity-oriented community stacks. forum
- Supportive non-peptides: NAC, vitamin D, omega-3s, and general respiratory-supplement talk often sits adjacent in the same threads. forum
- Real care first: Guideline inhalers (ICS/LABA/LAMA as indicated), smoking/vaping cessation, pulmonary rehab, infection care, vaccines when indicated, and oxygen when prescribed beat research peptides. forum
- Stack ratios rule: No standard fixed ratio; vendors vary — report each peptide’s own course, sequence, and form rather than inventing a pre-mix formula. forum
- Immune pairs: Near Thymalin / Thymosin-α1 / Thymogen in catalog blogs for mucosal/immune framing during respiratory seasons. forum
- Cortagen co-course: Same short bioregulator course as another tissue-directed tetrapeptide (brain/CNS framing for Cortagen) — calendar pairing, not synergistic PK data. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site: Mild redness, itch, sting, bruising, or tenderness is the most consistent community feedback; usually self-limited. forum
- Transient systemic noise: Sparse reports of brief flushing, temporary heart-rate awareness (~minutes post-injection in some writeups), mild headache, or early “flat” fatigue — anecdote layer, not quantified rates. anecdote
- Oral GI: Occasional mild digestive upset on capsule products; uncommon in sparse reports. anecdote
- Allergy rate: Not well quantified; generic peptide rash/itch/hypersensitivity caution applies; stop on clear allergic signs. forum
- What blogs claim is rare: Anaphylaxis, sleep disruption as a class problem, and steroid-like immunosuppression are not established signals — absence of reports ≠ proven clean long-term profile. forum
- Pregnancy / pediatric: Community and blog sources routinely advise against pregnancy, breastfeeding, and under-18 use — convention, not dedicated developmental trials. forum
- Not a care sub: Delaying infection, asthma, COPD, PE, pneumothorax, or cardiac dyspnea workup is the main practical risk of self-experimentation. forum
- Source quality: Mislabel (AEDL vs EDG/Chonluten vs other short peptides), contamination, under/overfill, and dose-math error on gray-market vials. forum
- Extract confusion: Reading tissue-extract human lore as proof for synthetic research vials overstates evidence and can inflate expected effect size. forum
- Chonluten swap: Expecting Chonluten (EDG) results from Bronchogen or vice versa is a documented information-hazard; animal COPD histology online is mostly AEDL-linked. forum
- Interactions: No systematic human data vs inhalers, systemic steroids, anticoagulants, biologics, or other peptides. forum
- Regulatory: Not FDA-approved for respiratory disease; typically sold research-only / not for human consumption. forum
- Human safety gap: No solid Western clinical safety tables, large RCTs, or systematic adverse-event registry for synthetic AEDL/Bronchogen. trial
- Sequence letter-order: ADEL paper titles vs AEDL vendor labels create COA-vs-literature mismatch risk. trial
- Preclinical limit: Rat NO₂ models, sparse fibrosis models, and cell studies do not establish human efficacy, dose, onset, durability, or long-term safety. animal
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.